Physician profile
Vanessa Daniel
NPI 1033560636
$1,064.45
in general payments reported to CMS, 2019-2025
20 companies · $52.42 in 2025
The $52.42 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $167 · 2022: $468 · 2023: $203 · 2024: $173 · 2025: $52.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $428.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $183.55 | 2022-2023 | Proclaim |
| Abbvie INC. | $152.44 | 2022-2024 | |
| Organon LLC | $129.10 | 2024 | |
| Scilex Pharmaceuticals INC. | $113.22 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $76.89 | 2021-2023 | Xtampza |
| Pfizer INC. | $74.52 | 2021-2023 | |
| Almatica Pharma LLC | $66.47 | 2022 | |
| Lilly USA, LLC | $50.84 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $38.04 | 2022 | |
| Hologic Sales and Service, LLC | $20.24 | 2025 | Thinprep 2000 Processor |
| Bioventus LLC | $18.26 | 2023 | Stimrouter Implantable Kit |
| Biodelivery Sciences International, INC. | $17.47 | 2021 | |
| Hikma Pharmaceuticals USA | $17.39 | 2022 | |
| Redhill Biopharma INC. | $17.17 | 2021 | |
| Merck Sharp & Dohme LLC | $17.05 | 2025 | Gardasil 9 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $16.03 | 2023 | Qutenza |
| Millicent US INC | $15.13 | 2025 | Femlyv |
| Biohaven Pharmaceuticals, INC. | $14.96 | 2021 | |
| Si-Bone, INC. | $13.38 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.